A case of castration-resistant prostate cancer with liver metastases achieved a complete response by docetaxel chemotherapy

0Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Castration-resistant prostate cancer (CRPC) patients with liver metastases have an extremely poor prognosis. Herein, we report a rare patient who achieved a complete response by docetaxel chemotherapy for this aggressive disease. A 67-year-old Japanese male diagnosed with local prostate cancer [initial prostate specific antigen (PSA) of 10.3 ng/mL, a highest Gleason score of eight] received radical prostatectomy (RP) followed by salvage radiotherapy for PSA recurrence without distant metastases. After four years, androgen deprivation therapy was commenced for both local recurrence and elevated PSA. After a further four years, despite good control of PSA (1.2 ng/mL), other clinical findings including radiographic images revealed CRPC with multiple liver metastases. Ten cycles of docetaxel chemotherapy achieved a complete response for more than five years. In conclusion, even if a patient has CRPC with liver metastases, early diagnostic imaging irrespective of the PSA level may provide a better response to early docetaxel chemotherapy.

Cite

CITATION STYLE

APA

Shirotake, S., Umezawa, Y., Okabe, T., Kaneko, G., Kanao, K., Nishimoto, K., & Oyama, M. (2020). A case of castration-resistant prostate cancer with liver metastases achieved a complete response by docetaxel chemotherapy. Translational Andrology and Urology, 9(2), 819–823. https://doi.org/10.21037/tau.2020.01.20

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free